{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:57Z","timestamp":1790957577683,"version":"4.1.0"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Genome editing technologies, clustered regularly interspaced short palindromic repeats (CRISPR)-Cas in particular, have revolutionized the field of genetic engineering, providing promising avenues for treating various genetic diseases. Chronic kidney disease (CKD), a significant health concern affecting millions of individuals worldwide, can arise from either monogenic or polygenic mutations. With recent advancements in genomic sequencing, valuable insights into disease-causing mutations can be obtained, allowing for the development of new treatments for these genetic disorders. CRISPR-based treatments have emerged as potential therapies, especially for monogenic diseases, offering the ability to correct mutations and eliminate disease phenotypes. Innovations in genome editing have led to enhanced efficiency, specificity and ease of use, surpassing earlier editing tools such as zinc-finger nucleases and transcription activator-like effector nucleases (TALENs). Two prominent advancements in CRISPR-based gene editing are prime editing and base editing. Prime editing allows precise and efficient genome modifications without inducing double-stranded DNA breaks (DSBs), while base editing enables targeted changes to individual nucleotides in both RNA and DNA, promising disease correction in the absence of DSBs. These technologies have the potential to treat genetic kidney diseases through specific correction of disease-causing mutations, such as somatic mutations in PKD1 and PKD2 for polycystic kidney disease; NPHS1, NPHS2 and TRPC6 for focal segmental glomerulosclerosis; COL4A3, COL4A4 and COL4A5 for Alport syndrome; SLC3A1 and SLC7A9 for cystinuria and even VHL for renal cell carcinoma. Apart from editing the DNA sequence, CRISPR-mediated epigenome editing offers a cost-effective method for targeted treatment providing new avenues for therapeutic development, given that epigenetic modifications are associated with the development of various kidney disorders. However, there are challenges to overcome, including developing efficient delivery methods, improving safety and reducing off-target effects. Efforts to improve CRISPR-Cas technologies involve optimizing delivery vectors, employing viral and non-viral approaches and minimizing immunogenicity. With research in animal models providing promising results in rescuing the expression of wild-type podocin in mouse models of nephrotic syndrome and successful clinical trials in the early stages of various disorders, including cancer immunotherapy, there is hope for successful translation of genome editing to kidney diseases.<\/jats:p>","DOI":"10.1093\/ckj\/sfae119","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T02:03:12Z","timestamp":1713405792000},"source":"Crossref","is-referenced-by-count":18,"title":["Genome editing and kidney health"],"prefix":"10.1093","volume":"17","author":[{"given":"Nadia","family":"Tavakolidakhrabadi","sequence":"first","affiliation":[{"name":"Bristol Renal, University of Bristol , Dorothy Hodgkin Building, Whitson Street, Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3097-3765","authenticated-orcid":false,"given":"Francesco","family":"Aulicino","sequence":"additional","affiliation":[{"name":"BrisSynBio Bristol Synthetic Biology Centre, Biomedical Sciences, School of Biochemistry, Bristol Royal Hospital for Children"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J","family":"May","sequence":"additional","affiliation":[{"name":"Bristol Renal, University of Bristol , Dorothy Hodgkin Building, Whitson Street, Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moin A","family":"Saleem","sequence":"additional","affiliation":[{"name":"Bristol Renal, University of Bristol , Dorothy Hodgkin Building, Whitson Street, Bristol , UK"},{"name":"Department of Paediatric Nephrology, Bristol Royal Hospital for Children , Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-9045","authenticated-orcid":false,"given":"Imre","family":"Berger","sequence":"additional","affiliation":[{"name":"School of Biochemistry, University of Bristol , Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin I","family":"Welsh","sequence":"additional","affiliation":[{"name":"Bristol Renal, University of Bristol , Dorothy Hodgkin Building, Whitson Street, Bristol , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"2024051708525536300_bib1","author":"Kidney Research UK","year":"2023","journal-title":"Kidney disease: a UK public health emergency. The health economics of kidney disease to 2033"},{"key":"2024051708525536300_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"key":"2024051708525536300_bib3","article-title":"Global Issues","author":"United Nations"},{"key":"2024051708525536300_bib4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fgene.2019.00453","article-title":"Genetic susceptibility to chronic kidney disease \u2013 some more pieces for the heritability puzzle","volume":"10","author":"Ca\u00f1adas-Garre","year":"2019","journal-title":"Front Genet"},{"key":"2024051708525536300_bib5","author":"Bindroo","year":"2024","journal-title":"Renal Failure"},{"key":"2024051708525536300_bib6","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.kint.2018.10.031","article-title":"Monogenic causes of chronic kidney disease in adults","volume":"95","author":"Connaughton","year":"2019","journal-title":"Kidney Int"},{"key":"2024051708525536300_bib7","doi-asserted-by":"crossref","first-page":"8318","DOI":"10.1038\/s41467-023-43878-9","article-title":"Polygenic risk alters the penetrance of monogenic kidney disease","volume":"14","author":"Khan","year":"2023","journal-title":"Nat Commun"},{"key":"2024051708525536300_bib8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.kint.2022.03.019","article-title":"Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"101","author":"K\u00f6ttgen","year":"2022","journal-title":"Kidney Int"},{"key":"2024051708525536300_bib9","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/ckj\/sfab056","article-title":"Genetic kidney diseases as an underrecognized cause of chronic kidney disease: the key role of international registry reports","volume":"14","author":"Torra","year":"2021","journal-title":"Clin Kidney J"},{"key":"2024051708525536300_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.7326\/M17-1319","article-title":"Whole-exome sequencing in adults with chronic kidney disease: a pilot study","volume":"168","author":"Lata","year":"2018","journal-title":"Ann Intern Med"},{"key":"2024051708525536300_bib11","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1038\/s41467-020-16605-x","article-title":"Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5","volume":"11","author":"Yamamura","year":"2020","journal-title":"Nat Commun"},{"key":"2024051708525536300_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1681\/ASN.2013070798","article-title":"Feasibility of repairing glomerular basement membrane defects in Alport syndrome","volume":"25","author":"Lin","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2024051708525536300_bib13","doi-asserted-by":"crossref","first-page":"1331099","DOI":"10.1080\/20022727.2017.1331099","article-title":"Nano-sized carriers in gene therapy for renal fibrosis in vivo","volume":"8","author":"Miyazawa","year":"2017","journal-title":"Nano Rev Exp"},{"key":"2024051708525536300_bib14","doi-asserted-by":"crossref","first-page":"121204","DOI":"10.1016\/j.lfs.2022.121204","article-title":"Clinical trials and promising preclinical applications of CRISPR\/Cas gene editing","volume":"312","author":"\u00c7er\u00e7i","year":"2023","journal-title":"Life Sci"},{"key":"2024051708525536300_bib15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ Res"},{"key":"2024051708525536300_bib16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol"},{"key":"2024051708525536300_bib17","doi-asserted-by":"crossref","first-page":"1272678","DOI":"10.3389\/fgeed.2023.1272678","article-title":"Progress in gene editing tools, implications and success in plants: a review","volume":"5","author":"Bhuyan","year":"2023","journal-title":"Front Genome Ed"},{"key":"2024051708525536300_bib18","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1002\/cpet.36","article-title":"Genome editing with CRISPR-Cas: an overview","volume":"19","author":"Robb","year":"2019","journal-title":"Curr Protoc Essential Lab Tech"},{"key":"2024051708525536300_bib19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.virol.2012.10.003","article-title":"Memory of viral infections by CRISPR-Cas adaptive immune systems: acquisition of new information","volume":"434","author":"Fineran","year":"2012","journal-title":"Virology"},{"key":"2024051708525536300_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/B978-0-12-817876-8.00003-6","article-title":"Chapter 4 \u2013 Single-guide RNAs: rationale and design","volume-title":"CRISPR Genome Surgery in Stem Cells and Disease Tissues","author":"Chang","year":"2022"},{"key":"2024051708525536300_bib21","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1017\/S0033583518000070","article-title":"Key role of the REC lobe during CRISPR-Cas9 activation by \u2018sensing\u2019, \u2018regulating\u2019, and \u2018locking\u2019 the catalytic HNH domain","volume":"51","author":"Palermo","year":"2018","journal-title":"Q Rev Biophys"},{"key":"2024051708525536300_bib22","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2014.02.001","article-title":"Crystal structure of Cas9 in complex with guide RNA and target DNA","volume":"156","author":"Nishimasu","year":"2014","journal-title":"Cell"},{"key":"2024051708525536300_bib23","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/15476286.2018.1504546","article-title":"PAM identification by CRISPR-Cas effector complexes: diversified mechanisms and structures","volume":"16","author":"Gleditzsch","year":"2019","journal-title":"RNA Biol"},{"key":"2024051708525536300_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/mps3030053","article-title":"Unexpectedly high levels of inverted re-insertions using paired sgRNAs for genomic deletions","volume":"3","author":"Blayney","year":"2020","journal-title":"Methods Protoc"},{"key":"2024051708525536300_bib25","first-page":"1387","article-title":"CRISPR gene therapy: applications, limitations, and implications for the future","volume-title":"Front Oncol","author":"Uddin","year":"2020"},{"key":"2024051708525536300_bib26","doi-asserted-by":"crossref","first-page":"9465028","DOI":"10.1155\/2018\/9465028","article-title":"New turns for high efficiency knock-In of large DNA in human pluripotent stem cells","volume":"2018","author":"He","year":"2018","journal-title":"Stem Cells Int"},{"key":"2024051708525536300_bib27","doi-asserted-by":"crossref","first-page":"7783","DOI":"10.1093\/nar\/gkac587","article-title":"Highly efficient CRISPR-mediated large DNA docking and multiplexed prime editing using a single baculovirus","volume":"50","author":"Aulicino","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2024051708525536300_bib28","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat Rev Genet"},{"key":"2024051708525536300_bib29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"key":"2024051708525536300_bib30","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/s41422-019-0213-0","article-title":"Precise in vivo genome editing via single homology arm donor mediated intron-targeting gene integration for genetic disease correction","volume":"29","author":"Suzuki","year":"2019","journal-title":"Cell Res"},{"key":"2024051708525536300_bib31","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41581-018-0047-x","article-title":"Precision gene editing technology and applications in nephrology","volume":"14","author":"WareJoncas","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2024051708525536300_bib32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nbt.2909","article-title":"Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification","volume":"32","author":"Guilinger","year":"2014","journal-title":"Nat Biotechnol"},{"key":"2024051708525536300_bib33","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"key":"2024051708525536300_bib34","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41551-023-01011-7","article-title":"Optimization of Cas9 activity through the addition of cytosine extensions to single-guide RNAs","volume":"7","author":"Kawamata","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"2024051708525536300_bib35","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.ymthe.2020.07.021","article-title":"Current status and challenges of DNA base editing tools","volume":"28","author":"Jeong","year":"2020","journal-title":"Mol Ther"},{"key":"2024051708525536300_bib36","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1042\/BCJ20170793","article-title":"CRISPR base editors: genome editing without double-stranded breaks","volume":"475","author":"Eid","year":"2018","journal-title":"Biochem J"},{"key":"2024051708525536300_bib37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities","volume":"19","author":"Porto","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2024051708525536300_bib38","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0092-8674(95)90467-0","article-title":"Crystal structure of human uracil-DNA glycosylase in complex with a protein inhibitor: protein mimicry of DNA","volume":"82","author":"Mol","year":"1995","journal-title":"Cell"},{"key":"2024051708525536300_bib39","doi-asserted-by":"crossref","first-page":"a012583","DOI":"10.1101\/cshperspect.a012583","article-title":"Base excision repair","volume":"5","author":"Krokan","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2024051708525536300_bib40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"2024051708525536300_bib41","doi-asserted-by":"crossref","first-page":"eaao4774","DOI":"10.1126\/sciadv.aao4774","article-title":"Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity","volume":"3","author":"Komor","year":"2017","journal-title":"Sci Adv"},{"key":"2024051708525536300_bib42","doi-asserted-by":"crossref","first-page":"1080626","DOI":"10.3389\/fcell.2022.1080626","article-title":"ADAR RNA editing on antisense RNAs results in apparent U-to-C base changes on overlapping sense transcripts","volume":"10","author":"Pecori","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2024051708525536300_bib43","doi-asserted-by":"crossref","first-page":"834413","DOI":"10.3389\/fgene.2022.834413","article-title":"The basis and promise of programmable RNA editing and modification","volume":"13","author":"Lo","year":"2022","journal-title":"Front Genet"},{"key":"2024051708525536300_bib44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s13059-020-02193-y","article-title":"A versatile toolkit for CRISPR-Cas13-based RNA manipulation in Drosophila","volume":"21","author":"Huynh","year":"2020","journal-title":"Genome Biol"},{"key":"2024051708525536300_bib45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"2024051708525536300_bib46","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41592-020-0861-5","article-title":"PAM-less is more","volume":"17","author":"Tang","year":"2020","journal-title":"Nat Methods"},{"key":"2024051708525536300_bib47","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","article-title":"Enhanced prime editing systems by manipulating cellular determinants of editing outcomes","volume":"184","author":"Chen","year":"2021","journal-title":"Cell"},{"key":"2024051708525536300_bib48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat Rev Genet"},{"key":"2024051708525536300_bib49","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.stem.2017.09.006","article-title":"CRISPR\/Cas9-based engineering of the epigenome","volume":"21","author":"Pulecio","year":"2017","journal-title":"Cell Stem Cell"},{"key":"2024051708525536300_bib50","doi-asserted-by":"crossref","first-page":"7834175","DOI":"10.1155\/2018\/7834175","article-title":"Novel epigenetic techniques provided by the CRISPR\/Cas9 system","volume":"2018","author":"Xie","year":"2018","journal-title":"Stem Cells Int"},{"key":"2024051708525536300_bib51","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/nep.13410","article-title":"Gene editing of stem cells for kidney disease modelling and therapeutic intervention","volume":"23","author":"Lau","year":"2018","journal-title":"Nephrology"},{"key":"2024051708525536300_bib52","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1038\/s41467-023-37449-1","article-title":"The C-terminal tail of polycystin-1 suppresses cystic disease in a mitochondrial enzyme-dependent fashion","volume":"14","author":"Onuchic","year":"2023","journal-title":"Nat Commun"},{"key":"2024051708525536300_bib53","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1038\/s41467-022-32543-2","article-title":"PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression","volume":"13","author":"Lakhia","year":"2022","journal-title":"Nat Commun"},{"key":"2024051708525536300_bib54","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1186\/gb-2013-14-10-r108","article-title":"Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development","volume":"14","author":"Ko","year":"2013","journal-title":"Genome Biol"},{"key":"2024051708525536300_bib55","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.3390\/ijms24066007","article-title":"The role of histone modifications in the pathogenesis of diabetic kidney disease","volume":"24","author":"Kourtidou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2024051708525536300_bib56","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/nm.3363","article-title":"Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes","volume":"19","author":"Hasegawa","year":"2013","journal-title":"Nat Med"},{"key":"2024051708525536300_bib57","doi-asserted-by":"crossref","first-page":"13327","DOI":"10.3390\/ijms222413327","article-title":"Recent discoveries in epigenetic modifications of polycystic kidney disease","volume":"22","author":"Bowden","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024051708525536300_bib58","doi-asserted-by":"crossref","first-page":"7603","DOI":"10.3390\/ijms24087603","article-title":"A review of CRISPR tools for treating usher syndrome: applicability, safety, efficiency, and in vivo delivery","volume":"24","author":"Major","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2024051708525536300_bib59","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","article-title":"Non-viral delivery systems for CRISPR\/Cas9-based genome editing: challenges and opportunities","volume":"171","author":"Li","year":"2018","journal-title":"Biomaterials"},{"key":"2024051708525536300_bib60","doi-asserted-by":"crossref","first-page":"683247","DOI":"10.3389\/fbioe.2021.683247","article-title":"Targeted drug delivery systems for kidney diseases","volume":"9","author":"Huang","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"2024051708525536300_bib61","doi-asserted-by":"crossref","first-page":"126475","DOI":"10.1016\/j.cej.2020.126475","article-title":"Kidney-targeted drug delivery systems based on tailor-made nanocapsules","volume":"404","author":"Oniszczuk","year":"2021","journal-title":"Chem Eng J"},{"key":"2024051708525536300_bib62","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/diseases6020042","article-title":"Viral vectors in gene therapy","volume":"6","author":"Lundstrom","year":"2018","journal-title":"Diseases"},{"key":"2024051708525536300_bib63","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024051708525536300_bib64","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jconrel.2020.09.003","article-title":"Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors","volume":"327","author":"Boucher","year":"2020","journal-title":"J Control Release"},{"key":"2024051708525536300_bib65","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"2024051708525536300_bib66","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3390\/v13071288","article-title":"Lentiviral vectors for delivery of gene-editing systems based on CRISPR\/Cas: current state and perspectives","volume":"13","author":"Dong","year":"2021","journal-title":"Viruses"},{"key":"2024051708525536300_bib67","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/14712598.2022.2012148","article-title":"Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders","volume":"22","author":"Marrone","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2024051708525536300_bib68","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3390\/cells10112844","article-title":"CFTR protein: not just a chloride channel?","volume":"10","author":"Hanssens","year":"2021","journal-title":"Cells"},{"key":"2024051708525536300_bib69","doi-asserted-by":"crossref","first-page":"14716","DOI":"10.1038\/ncomms14716","article-title":"Nrl knockdown by AAV-delivered CRISPR\/Cas9 prevents retinal degeneration in mice","volume":"8","author":"Yu","year":"2017","journal-title":"Nat Commun"},{"key":"2024051708525536300_bib70","doi-asserted-by":"crossref","first-page":"14454","DOI":"10.1038\/ncomms14454","article-title":"Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy","volume":"8","author":"Bengtsson","year":"2017","journal-title":"Nat Commun"},{"key":"2024051708525536300_bib71","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease","volume":"127","author":"Yang","year":"2017","journal-title":"J Clin Invest"},{"key":"2024051708525536300_bib72","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/mt.2012.286","article-title":"Baculovirus: an insect-derived vector for diverse gene transfer applications","volume":"21","author":"Airenne","year":"2013","journal-title":"Mol Ther"},{"key":"2024051708525536300_bib73","doi-asserted-by":"crossref","first-page":"11529","DOI":"10.1038\/ncomms11529","article-title":"Highly efficient baculovirus-mediated multigene delivery in primary cells","volume":"7","author":"Mansouri","year":"2016","journal-title":"Nat Commun"},{"key":"2024051708525536300_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plasmid.2018.05.002","article-title":"Baculovirus for gene delivery to mammalian cells: past, present and future","volume":"98","author":"Mansouri","year":"2018","journal-title":"Plasmid"},{"key":"2024051708525536300_bib75","doi-asserted-by":"crossref","first-page":"15050","DOI":"10.1038\/mtm.2015.50","article-title":"Manufacturing of AcMNPV baculovirus vectors to enable gene therapy trials","volume":"3","author":"Kwang","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024051708525536300_bib76","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3390\/cells11091571","article-title":"Genetic kidney diseases (GKDs) modeling using genome editing technologies","volume":"11","author":"G\u00f3mez-Garc\u00eda","year":"2022","journal-title":"Cells"},{"issue":"3 Suppl","key":"2024051708525536300_bib77","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/j.ekir.2023.02.462","article-title":"WCN23-0056 Proteomic profile of edited podocytes by CRISPR\/Cas9 technology expressing Fabry's disease phenotype","volume":"8","author":"Monte Neto","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2024051708525536300_bib78","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1681\/ASN.2020030378","article-title":"PKD1-dependent renal cystogenesis in human induced pluripotent stem cell-derived ureteric bud\/collecting duct organoids","volume":"31","author":"Kuraoka","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2024051708525536300_bib79","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/stem.2707","article-title":"Gene-edited human kidney organoids reveal mechanisms of disease in podocyte development","volume":"35","author":"Kim","year":"2017","journal-title":"Stem Cells"},{"key":"2024051708525536300_bib80","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(10)60236-X","article-title":"Genetic kidney diseases","volume":"375","author":"Hildebrandt","year":"2010","journal-title":"Lancet"},{"key":"2024051708525536300_bib81","first-page":"33","article-title":"5. Hereditary kidney disorders","volume":"20","author":"Stavljeni\u0107-Rukavina","year":"2009","journal-title":"EJIFCC"},{"key":"2024051708525536300_bib82","first-page":"eabc8226","article-title":"Adeno-associated virus gene therapy prevents progression of kidney disease in genetic models of nephrotic syndrome","volume-title":"Sci Transl Med","author":"Ding","year":"2023"},{"key":"2024051708525536300_bib83","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.ajkd.2018.02.347","article-title":"CRISPR gene editing in the kidney","volume":"71","author":"Cruz","year":"2018","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae119\/57262719\/sfae119.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/5\/sfae119\/57723344\/sfae119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/5\/sfae119\/57723344\/sfae119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:04:19Z","timestamp":1715940259000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae119\/7649380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae119","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,4,17]]},"article-number":"sfae119"}}